We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Axsome Therapeutics Expects FDA Will Reject Migraine Drug for Approval
Axsome Therapeutics Expects FDA Will Reject Migraine Drug for Approval
Axsome Therapeutics said it anticipates the FDA will decline to approve its experimental drug AXS-07 for the acute treatment of migraines because of problems related to its chemistry, manufacturing and controls (CMC) processes.